ARIAD Pharmaceuticals

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

ARIAD Pharmaceuticals was acquired by Takeda Pharmaceutical on January 9, 2017

Type
Subsidiary
Parent Company
Takeda Pharmaceutical
HQ
Cambridge, US
Founded
1991
Website
ariad.com
ARIAD Pharmaceuticals was founded in 1991 and is headquartered in Cambridge, US

ARIAD Pharmaceuticals Office Locations

ARIAD Pharmaceuticals has offices in Cambridge, Minneapolis, Boston, San Antonio and in 9 other locations
Cambridge, US (HQ)
26 Landsdowne St
Show all (13)

ARIAD Pharmaceuticals Data and Metrics

ARIAD Pharmaceuticals Summary

Founding Date

1991
ARIAD Pharmaceuticals is a subsidiary of Takeda Pharmaceutical

ARIAD Pharmaceuticals Financial Metrics

ARIAD Pharmaceuticals's revenue was reported to be $118.8 m in FY, 2015 which is a 13% increase from the previous period.
USDFY, 2013FY, 2014FY, 2015

Revenue

45.6 m105.4 m118.8 m

Revenue growth, %

131%13%

EBIT

(273.6 m)(160.2 m)(217.3 m)

EBIT margin, %

(600%)(152%)(183%)
USDFY, 2013FY, 2014FY, 2015

Cash

237.2 m352.7 m230.9 m

Accounts Receivable

1.3 m8.4 m15.7 m

Inventories

419 k

Current Assets

244.9 m385.6 m275.2 m
USDFY, 2013FY, 2014FY, 2015

Net Income

(274.2 m)(162.6 m)(231.2 m)

Accounts Receivable

(1.3 m)(7.1 m)(7.3 m)

Inventories

(413 k)(560 k)1.1 m

Accounts Payable

2.5 m(137 k)5.5 m
Show all financial metrics

ARIAD Pharmaceuticals Median Salaries

Source: 16 public H-1B filings from ARIAD Pharmaceuticals

Traffic Overview of ARIAD Pharmaceuticals

ARIAD Pharmaceuticals Online and Social Media Presence

ARIAD Pharmaceuticals News and Updates

Some of Wall Street's top boutique firms just landed a big payday

Two big-name deals announced Monday are set to line the pockets of numerous boutique investment banks. The luxury retailer Coach said in a statement that it agreed to buy Kate Spade for $18.50 a share, for a total transaction value of $2.4 billion. And Sinclair Broadcast Gro…

Who bought who? The biggest deals made so far this year revealed...

So this morning Johnson & Johnson bought Europe's biggest healthcare firm in a $31bn (£23.7bn) transaction in what was the biggest M&A deal announced so far in 2017. Which are the other big deals made this year? Dealogic has a handy list: 1. Actelion Acquiror: Johnson & Johnson …

Japan's Takeda buys US cancer specialist Ariad

Japanese pharmaceutical firm Takeda buys US cancer drug maker Ariad for $5.2bn (£4.3bn).

Breakingviews: Takeda’s Bid for Cancer Drug Maker Looks Expensive

The Japanese pharmaceutical offers to buy Ariad Pharmaceuticals for $5.2 billion, about 75 percent above the price where the biotech’s shares were trading.

The biggest healthcare investor conference starts this week — here are the 5 things we expect to get out of it

The second week of January is a busy time for drug companies.  Starting Monday, thousands of pharmaceutical industry executives, investors, bankers, and analysts will swarm into San Francisco for the JPMorgan healthcare conference. Now in its 35th year, the conference has ba…

Japan's Takeda to Buy U.S. Cancer Drug Maker Ariad in $5.2 Billion Deal

Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.
Show more

ARIAD Pharmaceuticals Company Life and Culture

You may also be interested in